GLP-1 Drugs Linked to Lower Alzheimer's Risk Amid Safety Warnings
Novo Nordisk ( NYSE:NVO) and Eli Lilly ( NYSE:LLY) are making headlines againthis time, for potential benefits beyond weight loss. A new study finds that people taking GLP-1 medications like Ozempic, Wegovy, and Mounjaro face up to a 12% lower risk of developing Alzheimer's disease.
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...
Glucagon-like peptide-1 receptor agonist use corresponded with risk reductions for dozens of diseases and adverse health ...
Computational research conducted by scientists from Washington University in St. Louis shows that GLP-1 agonists can have ...
Medpage Today on MSN1d
GLP-1 Agents' Risks and Benefits Broader Than Previously ThoughtGLP-1 agents "have an intricate web of various effects," Al-Aly said in a press briefing. For example, the analysis showed ...
Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...
From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.
Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinfo ...
Data from a Phase Ia single ascending dose study found that ASC30 demonstrated dose-proportional pharmacokinetics, a ...
A new analysis finds nearly half of the compounded GLP-1 websites didn’t include information on adverse effects, warnings, ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback